BGI is granted patent in 16 countries for non-invasive prenatal genetic test technology

BGI Dx has developed a series of BGI gene test services based on multidisciplinary technologies and approaches, including independent core technologies such as high throughput sequencing, high sensitivity mass spectrum and big data analysis. BGI Dx\'s test product provision covers the entire human lifecycle from conception, pregnancy and birth, to old age.

About non-invasive prenatal genetic test （NIFTY®)

Through collecting a small sample of peripheral blood from the pregnant woman, NIFTY® is able to extract cell free fetal DNA. Utilizing next generation high throughput sequencing technology combined with bioinformatics analysis, NIFTY® provides a highly accurate risk rate of occurrence for chromosomal aneuploidy in the fetus.

As a non-invasive prenatal test, NIFTY® avoids the risk of miscarriage associated with invasive diagnostic procedures such as amniocentesis, which carries a 1% risk of miscarriage.

As of August 2014, non-invasive prenatal genetic tests provided by BGI Dx are offered by more than 2000 healthcare providers in more than 52 countries including England, Australia, Spain, Singapore, Israel, Czech Republic, Turkey, Thailand and China, with nearly 400,000 test samples processed so far, and with an accuracy rate of more than 99.9%. Non-invasive prenatal testing is particularly suitable for pregnant women who have certain indications including pregnant women who have received a high risk result from serological screening; pregnant women who have experienced habitual abortion; pregnant women with puncture contraindications; pregnant women not suitable for or unwilling to undergo invasive prenatal diagnosis such as amniocentesis and pregnant women of advanced maternal age.